- Kymera Therapeutics Inc KYMR commenced an underwritten public offering of 4 million shares of common stock.
- Underwriters can purchase up to an additional 600k shares.
- Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities are acting as joint book-running managers for the proposed offering.
- The proceeds will be used to fund the continued development of KT-474, KT 413, expansion of IRAK4 & IRAKIMiD oncology franchises.
- Recently, the company announced interim results from the Single Ascending Dose portion of the Phase 1 trial of KT-474 in healthy volunteers.
- KT-474 has exceeded the Phase 1 target degradation of 85% to date, with robust IRAK4 degradation after a single oral dose lasting for at least six days at all dose levels.
- The company says that based on existing cash and cash equivalents and marketable securities of $435.2 million and net proceeds from this offering, it will be sufficient to fund our operations into 2025.
- See the offering prospectus here.
- Price Action: KYMR shares are down 0.4% at $47 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in